BLTE
Belite Bio Soars into Second Quarter with Strong Earnings and FDA Approval on the Horizon
The biotech industry is abuzz with excitement as Belite Bio, a leading developer of innovative treatments for retinal diseases, continues to impress investors and patients alike. In its recent Q2 2026 earnings call transcript, the company revealed a plethora of promising updates that further solidify its position as a pioneer